Form 4: Cabaletta Bio Director, Scott C. Brun, Reports Stock Option Grant

Director Scott C. Brun reports the acquisition of stock options for 22,000 shares of Cabaletta Bio, Inc. at an exercise price of $10.01.

Summary

• On June 3, 2024, Scott C. Brun, a director of Cabaletta Bio, Inc., was granted stock options to purchase 22,000 shares of the company's common stock.
• The exercise price for these options is $10.01 per share.
• The options vest in full on the earlier of June 3, 2025, or the date of the next annual meeting of the Corporation's stockholders.
• The options expire on June 2, 2034.
• Following the transaction, Brun directly owns 22,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning the interests of employees and directors with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotechnology companies.
• The size of the grant (22,000 shares) would need to be compared to grants made to directors at comparable companies (e.g., those with similar market capitalization and stage of development) to assess its relative value.
• Vesting schedules are also typical, with vesting often tied to continued service or performance milestones.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates